A Seamless Adaptive Phase 2b/3 Double-Blind Randomized Placebo-controlled Multicenter International Study Evaluating the Efficacy and Safety of Belapectin (GR-MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis

Brief description of study

The purpose of this study is to find out about the safety and efficacy (how well a drug works) of Belapectin (GR-MD-002) for the prevention of esophageal varices in NASH (Non-Alcoholic Steatohepatitis) Cirrhosis. Belapectin is an investigational drug that has not been approved for prevention of esophageal varices in NASH by Health Authorities in any country of the world, including the United States Food and Drug Administration (U.S. FDA).

Clinical Study Identifier: s19-00786
ClinicalTrials.gov Identifier: NCT04365868
Principal Investigator: Viviana Figueroa Diaz.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.